Introduction
The newest MDCG guidance on clinical evaluation raises expectations again. Manufacturers must now demonstrate a living system of data appraisal, performance verification, and post-market follow-up that evolves with every design change and complaint.
In the 2024 Team-NB survey, more than 30 % of MDR non-conformities cited by Notified Bodies were linked to clinical-evaluation or clinical-evidence deficiencies, the single largest category of significant findings.
Without an updated Clinical Evaluation Report (CER) aligned to current MDCG 2024/2025 guidance, even established certificates can slip.
Need help updating your Clinical Evaluation Report for MDR? Speak to Patient Guard’s clinical team →
What Is Clinical Evaluation Under MDR?
Under Annexe XIV Part A of the EU MDR 2017/745 regulation, clinical evaluation means “a systematic and planned process to continuously generate, collect and appraise clinical data to verify the safety and performance of a device throughout its lifecycle.”
In practice, MDR replaces the static, pre-market model of the MDD with a dynamic, lifecycle approach that links four documents in sequence:
- Clinical Evaluation Plan (CEP) – defines methodology, endpoints, and sources.
- Clinical Data Collection – from studies, literature, or post-market use.
- Clinical Evaluation Report (CER) – evaluates data quality and draws conclusions.
- Post-Market Clinical Follow-Up (PMCF) – ensures findings remain valid in real-world use.
Stay ahead of MDR 2025 requirements. Partner with Patient Guard to keep your clinical evidence current, cohesive, and audit-ready. Contact us today →
Key Changes in MDCG Guidance on Clinical Evaluation
The European Commission’s MDCG guidance library is continuously updated to clarify MDR expectations. Between 2024 and 2025, several key trends emerged:
- Evidence depth over breadth – the justification of clinical data must now include measurable clinical benefit, not just a literature review.
- Stricter equivalence rules – technical, biological, and clinical similarity must be proven with access to complete technical documentation.
- Explicit PMCF linkage – PMCF activities must address the residual risks and data gaps identified in the CER.
- Legacy device clarifications – new MDCG texts outline when additional clinical investigations are unavoidable.
Example: MDCG 2024-x now requires manufacturers to demonstrate a measurable clinical benefit beyond simple equivalence claims, which is a shift from descriptive to outcome-based justification.
Clinical Evidence Requirements Under EU MDR
Annexe XIV and Article 61 describe the hierarchy of acceptable evidence:
- Clinical investigations – gold-standard, prospective studies.
- Published literature – peer-reviewed data of suitable quality.
- Post-market data and registries – real-world evidence under PMS/PMCF.
- Equivalence justification – only if full access to source data exists.
The rule is proportionality: higher-risk devices require direct, device-specific data. Notified Bodies now expect clear traceability between evidence sources and device claims, with statistical justification and alignment across CER, Instructions for Use (IFU), and PMS reports.
The Clinical Evaluation Report (CER) – Structure and Strategy
What a CER must contain
A compliant CER includes:
- Device description and intended purpose
- Clinical data identification and appraisal
- Analysis of benefit–risk profile
- Correlation with risk-management and PMS findings
- Conclusions and update schedule
The CER must be a living document, reviewed at least annually for Class III and IIb implants or whenever new safety information arises.
Common CER non-conformities
- Unsupported data sources or outdated literature
- Reliance on MDD-era equivalence
- Poor linkage to CAPA or risk management
- Mismatch between CER conclusions, IFU claims, and PMS data
Tips for alignment
Map content to MDCG 2020-13 and the latest 2024-x update, ensure every claim has verifiable data, and link conclusions directly to PMS and PMCF outputs.
See also: Patient Guard’s Clinical Evaluation and CER Writing Services
Equivalence Under MDR: Stricter, Clearer, and Harder to Prove
Equivalence once allowed MDD manufacturers to piggyback on similar devices. Under MDR, that shortcut has virtually disappeared.
Per MDCG 2020-5 and 2020-6, manufacturers must demonstrate:
- Technical equivalence – same design and materials.
- Biological equivalence – same contact type and duration.
- Clinical equivalence – same intended purpose and clinical performance.
Access to the other manufacturer’s technical documentation is required—a condition rarely met without cooperation agreements. As a result, many legacy devices now require new clinical investigations or enhanced PMCF studies to remain on the market.
Post-Market Clinical Follow-Up (PMCF) and Continuous Evaluation
PMCF is the ongoing form of clinical evaluation in real-world use. It collects data on safety, performance, and residual risks identified during pre-market assessment.
The 2024 EU Commission/Team-NB review found that over 50 % of PMCF plans failed to close identified evidence gaps, even after multiple review rounds—making PMCF a top driver of CER non-compliance.
Effective PMCF plans must:
- Specify measurable objectives and justified sample sizes.
- Integrate statistical analysis plans.
- Demonstrate feedback into PMS and risk management.
See also: Patient Guard’s blog article on How to Navigate the EU & UK MDR: A Practical Compliance Guide
Clinical Evaluation Documentation and Lifecycle Integration
Clinical evaluation is not a standalone activity; it is woven through the device lifecycle:
CEP → Clinical Data → CER → PMCF → PMS → Risk Management
A risk-based QMS ensures each output feeds the next. For example:
- Risk files inform clinical study design.
- PMCF findings update risk evaluation.
- Management reviews confirm the effectiveness of risk controls.
Visualising this “evidence ecosystem” helps founders understand that clinical evaluation isn’t a regulatory hurdle but a continuous learning loop improving both safety and market credibility.
Preparing for 2025 Notified Body Reviews
Expect three dominant themes in upcoming assessments:
- Alignment with current MDCG guidance – CERs referencing outdated templates trigger non-conformities.
- Legacy device evidence scrutiny – equivalence justifications face deeper challenge.
- Continuous maintenance proof – auditors will check version histories and update logs.
According to Team-NB 2024, average review turnaround for MDR clinical documentation reached 13–18 months, driven largely by incomplete CER and PMCF data sets. Comprehensive, harmonised documentation can shorten this timeline dramatically.
Book a Patient Guard MDR CER Review to ensure your documentation meets 2025 expectations → Get in Touch
Conclusion
The MDR transformed clinical evaluation from a pre-market formality into a continuous, data-driven discipline. Compliance now demands agility: living CERs, proactive PMCF, and tight integration with risk and quality systems.
Manufacturers who invest early in structured processes not only pass audits more smoothly—they build enduring trust with regulators, clinicians, and patients.
Contact Patient Guard for end-to-end support—from Clinical Evaluation Plans to full CER and PMCF implementation → Speak to an expert today.
Frequently Asked Questions
MDR requires continuous lifecycle evaluation, more substantial evidence for clinical benefit, and mandatory linkage between CER, PMCF, and PMS. The MDD’s one-time submission model no longer applies.
MDCG 2020-13 (CER Template), MDCG 2020-5/6 (Equivalence), MDCG 2024-x (update on evidence depth), and MDCG 2020-7 (PMCF methods) remain essential references.
At least annually for high-risk devices or immediately following significant design, safety, or performance changes.
Clinical investigations, peer-reviewed studies, post-market data, or properly justified equivalence with full access to source technical information.
They expect documented proof of technical, biological, and clinical similarity, plus direct access to the other device’s technical file—rarely achievable without formal agreements.
Yes. Patient Guard’s clinical team supports everything from planning and gap analysis to complete CER authoring and PMCF execution, aligned to the latest MDCG guidance.
Patient Guards Recent Posts
CE Marking vs UKCA: 2026 Guide for Manufacturers
Post-Brexit, many medical device manufacturers are still navigating the split between CE marking and the UKCA mark — and the rules keep evolving. As the MHRA advances its “future regime” for medical devices, regulatory teams face the ongoing challenge of complying with both EU MDR obligations and the UK’s own UK MDR 2002 (as amended) framework.
ISO 10993-1:2025 – What’s New in Biological Evaluation
The newly revised ISO 10993-1:2025 has quietly done something big: it’s turned biological evaluation from a “tick-the-box biocompatibility test list” into a fully integrated risk narrative that regulators now expect to hold together scientifically, from chemistry through to clinical data.
EUDAMED Mandatory from May 2026: What You Need to Know
After years of “coming soon”, the EU has finally put a fixed date on reality: the first EUDAMED mandatory modules must be used from 28 May 2026.
Sources
– Team-NB Survey 2024 – MDR Non-Conformities and Certification Timelines
– EU Commission / Team-NB 2024 PMCF Effectiveness Review
– EU MDR 2017/745 Annex XIV
– European Commission – MDCG Guidance Library
